# Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis

> **NCT07129629** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 45 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary
- Drug-Susceptible Pulmonary Tuberculosis

## Interventions

- **DRUG:** Bedaquiline (B)
- **DRUG:** Moxifloxacin
- **DRUG:** Pyrazinamide (PZA)
- **DRUG:** Delamanid (D)
- **DRUG:** Isoniazid (H)
- **DRUG:** Rifampicin (R)
- **DRUG:** Ethambutol (E)

## Key facts

- **NCT ID:** NCT07129629
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07129629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07129629, "Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07129629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*